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Summary: A simple, sensitive and precise isocratic HPLC method for the determination of total homocysteine in
human plasma is described. The thiol compounds were liberated from plasma proteins by reduction with tn-n-
butylphosphine and derivatized with a thiol-specific fluorogenic marker, 7-fluoro-benzo-2-oxa-l,3-diazole-4-sulpho-
nate. The derivatives were separated isocratically within 7 min by reversed-phase HPLC using a Superspher 100
RP-18 column as stationary phase.
By using this approach more than 200 samples a day can be assayed for total homocysteine. The method was linear
up to 100 μιηοΐ/ΐ and proved to be sensitive with a detection limit of 0.1 μηιοΐ/ΐ and the lowest limit of reliable
quantification of 0.5 umol/1 for homocysteine in buffer. Intra- and inter-assay coefficients of variation were both
<4% at a concentration of 10 umol/1 homocysteine. Similar results were obtained for homocysteine concentrations
between 0.5 and 100 μηιοΐ/ΐ. The analytical recovery for these concentrations ranged from 94.9 to 117.0%.
As compared to other protocols published so far, this modified method is less complicated but equally sensitive
and reproducible and allows a rapid determination of total homocysteine and cysteine in human plasma under
routine conditions.
Introduction
Even mildly elevated concentrations of plasma homo-
cysteine, referred to as hyperhomocyst(e)inaemia, are
considered to be an independent risk factor for prema-
ture atherosclerosis resulting in coronary heart disease,
stroke and peripheral vascular disease (1—4). Underly-
ing causes for elevated plasma concentrations of homo-
cysteine may be either deficiencies of enzymes of the
degradation pathway of sulphur containing aminoacids
like cystathionine -synthase1) and 5-methylenetetrahy-
drofolate-homocysteine S-methyltransferase1) or of then-
respective cofactors such as vitamin Be , vitamin B12,
folic acid or betaine (5). Recently, a 677 C-T mutation
in the methylenetetrahydrofolate reductase1) gene, lead-
ing to a thermolabile form of the enzyme, was shown to
be an independant risk factor for neural tube defects (6).
1) Enzymes
Cystathionine -synthase = α-serine hydro-lyase (adding homo-
cysteine): EC 4.2.1.22
5-Methylenetetrahydrofolate-homocysteine S-methyltransferase =
5-methyltetrahydro pteroyl-a-glutamate : cr-homocysteine S-
methyltransferase: EC 2.1.1.14
Methylenetetrahydrofolate reductase (NAD+) = 5,10-methylenete-
trahydrofolate : NAD+ oxidoreductase: EC 1.5.1.15
γ-Glutamyltransferase = (5-a-glutamyl)-peptide : amino-acid 5-
glutamyltransferase: EC 2.3.2.2.
The detection of homozygous patients with cystathio-
nine -synthase deficiency (homocystinuria) will not
present difficulties in most cases due to the typical clin-
ical symptoms and the markedly elevated basal concen-
trations of total homocysteine in plasma and urine (7).
However, the identification of patients with mildly ele-
vated concentrations of homocysteine due to heterozy-
gous deficiencies of cystathionine- -synthase or 5-
methyltetrahydrofolate-homocysteine S-methyltransfer-
ase or their respective cofactors is considered to be more
difficult. In these cases fasting plasma levels of total
homocysteine may not differ significantly from healthy
subjects. Recent work demonstrates that these patients
can only be reliably assessed by an oral methionine load-
ing test (8).
In plasma, homocysteine mainly occurs as a disulphide
conjugated to albumin (—70%), to a lesser extent as ho-
mocystinyl moiety or mixed disulphides and only a
small amount exists as free homocysteine. It has been
found that the small amount of free homocysteine does
not reflect the diagnostically relevant total homocysteine
pool (9,10). Moreover, free homocysteine escapes detec-
tion when the plasma is stored, since it is spontaneously
bound to protein molecules (9,10). Routine amino acid
analysis, however, usually measures free amino acids
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and is therefore not suitable for the detection of mild
hyperhomocyst(e)inaemia. In addition, the commonly
used post-column derivatization with ninhydrin does not
seem to be sensitive enough for the reliable quantitation
of physiological plasma concentrations of free or total
homocysteine (1, 11).
Thus, a variety of high performance liquid chromatogra-
phy (HPLC) methods have been established for the de-
tection of total homocysteine in plasma (2,5,12—14).
Most techniques, however, have proven to be difficult
for routine application e. g. due to the requirement of
gradient systems, demanding derivatization procedures
or interferences. Therefore, the aim of this study was to
establish a modified protocol allowing simple and high




tylphosphine and Ν,Ν-dimethylformamide were obtained from
Fluka (Ulm, Germany). Ζ,-Cysteine, Ζ,-homocysteine, glutathione,
γ-glutamyltransferase1) and Na2EDTA were purchased from Sigma
(Deisenhofen, Germany). All other reagents were of analytical
grade and obtained from commercial sources. Cysteinylglycine
was prepared according to I.e. (15) with slight modifications.
HPLC equipment and Chromatographie conditions
The HPLC system consisted of a M 480 pump connected to a
GINA 160 autosampler with cooled racks (both Gynkotek, Germe-
ring, Germany) and a fluorescence spectrophotometer (F 1000,
Merck/Hitachi, Darmstadt, Germany). As stationary phase a Su-
perspher 100 RP-18 endcapped column (250X4 mm, 4μπι) pro-
tected by a guard-column LiChrospher 60 RP-select B, 5 μηι (both
Merck, Darmstadt, Germany) was used.
The mobile phase consisted of a 30 mmol/1 ammonium-formiate —
40 mmol/1 ammonium-nitrate buffer (adjusted to pH 3.65 with for-
mic acid) and acetonitrile (95 + 5, by vol.). The mobile phase was
filtered (0.2 μηι, Costar, Cambridge, USA) and degassed prior to
use. Flow rate was 1 ml/min and column temperature was main-
tained at 35 °C. The column effluent was monitored by fluores-
cence detection with an excitation wavelength of 385 nm and an
emission wavelength of 515 nm. Data were recorded and processed
using an integration software (Gynkosoft, Gynkotek, Germering,
Germany).
Sample collection
Blood from healthy subjects was collected into prechilled EDTA-
containing tubes (Vacuette, Greiner, Solingen, Germany) by veni-
puncture and immediately centrifuged at 2000 g for 10 min at
0 °C. Plasma was pooled and stored at -20 °C until analysis.
Sample preparation
Plasma (200 μΐ) was treated on ice with 20 μΐ 100 ml/1 tri-n-butyl-
phosphine in dimethylformamide for 30 min at 0 °C in order to
reduce thiols and decouple them from the plasma proteins. Per-
chloric acid (200 μΐ, 0.5 mol/1, containing 1 mmol/1 Na2EDTA) was
added to the sample, and the mixed sample was incubated for 10
min on ice. Protein was removed by centrifugation at 10000 g for
10 min at 0 °C. Hundred (100) μΐ of the supernatant were mixed
with 250 μΐ 2 mol/1 borate buffer (containing 5 mmol/1 Na2EDTA,
pH 10.5) and ΙΟΟμΙ 7-fluoro-benzo-2-oxa-1.3-diazole-4-sulpho-
nate (l.Og/1 in 0.1 mol/1 borate buffer, containing 2 mmol/1
Na2EDTA, pH 9.5) and incubated at 60 °C for 60 min. To terminate
the reaction, the solution was snap-cooled on ice and transferred
to a cooled autosampler vial. An aliquot of 20 μΐ was injected onto
the column.
Preparation of standards and assessment of variability
To determine the intra-assay and inter-assay variability standard
samples of 13 different concentrations of Ζ,-homocysteine (O.I to
1000 umol/l) and L-cysteine (0.3 to 3000 μτηοΐ/ΐ) were prepared
by serial dilution in 0.1 mol/1 borate buffer, containing 2 mmol/1
Na2EDTA, pH 9.5. In a similar way plasma samples spiked with
11 different concentrations of Ζ,-homocysteine (0.5 to 1000 umol/l)
and Z,-cysteine (1.5 to 3000 umol/l) were prepared.
To assess the intra-assay (within day) variability 10 replicates of
these serial dilutions as well as blank plasma were measured. Sam-
ples of the same concentrations were stored at - 20 °C and one
sample of each concentration was analysed on 10 different days
over a period of five months to assess inter-assay (day to day) vari-
ability.
The concentration of total homocysteine in plasma samples was
calculated from a peak area of 50 umol/l homocysteine in buffer
as external standard.
Recovery
L-Homocysteine and Ζ,-cysteine were either dissolved in 0.1 mol/1
borate buffer, containing 2 mmol/1 Na2EDTA, pH 9.5, or in pooled
plasma to give a concentration of 6000 μπιοΐ/ΐ and 3000 μτηοΐ/ΐ,
respectively. These stock solutions were further diluted with buffer
or pooled plasma to known concentrations. The concentration of
thiols determined in 10 replicates of a water matrix (standards, S),
was used to adjust the system. Then the concentrations of homo-
cysteine in pooled plasma (P) and in plasma supplemented with
standards (PS) were determined in 10 replicates and analytical re-
covery was calculated as follows:
Recovery (%) = ((PS - P)/S) X 100.
Results
Chromatography
Under the Chromatographie conditions described reten-
tion times proved to be stable with a coefficient of varia-
tion for homocysteine of 0.5% (within run) and 4.6%
(between run) for a period of five months. In addition
to homocysteine also other substituents of importance
like cysteine, cysteinylglycine or glutathione are clearly
separated in the same run. Baseline separation of homo-
cysteine from these other thiol containing peaks could
be achieved and maintained for a column life of more
than 500 injections of plasma samples (fig. 1).
Linearity and sensitivity
The determination of homocysteine was linear up to
100 μηιοΐ/l both for samples prepared in buffer (correla-
tion coefficient r = 0.99, p < 0.001) and in plasma (cor-
relation coefficient r = 0.99, p < 0.001) as shown in fig-
ure 2. At higher concentrations the fluorescence inten-
sity exceeded the upper limit of the detector used. With
another fluorescence spectrophotometer (F 1080, Merck/
Hitachi, Darmstadt, Germany) the response was found
to be linear up to 1000 μπιοΙ/1 (data not shown).
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Fig. 1 Representative chromatograms of 7-fluoro-benzo-2-oxa-
1.3-diazole-4-sulphonate-derivative of thiols in plasma
(a) Plasma sample spiked with 50 μιηοΐ/ΐ of homocysteine and
150 μιηοΐ/ΐ of cysteine.
(b) Plasma sample of a person with a homocysteine concentration
in the physiological range (homocysteine 5.4 μηιοΐ/ΐ, cysteine
132.3 μηιοΐ/l).
Chromatogram (a) was recorded with a new column, chromato-
gram (b) after injection of around 300 plasma samples.
Peaks are (1) cysteine, (2) homocysteine, (3) cyteinylglycine and
(4) glutathione.
The detection limit of the method for homocysteine
standards was 0.1 μπιοΙ/1 and the lowest limit of reliable
quantification was 0.5 μηιοΙ/1. For homocysteine plasma
samples the lowest concentration of homocysteine
which resulted in an area increase that could be reliably
distinguished from the blank plasma values (>2.57 SD,
η = 10) was 0.69 μπιοΙ/1.
Precision and recovery
The within day (ultra-assay) coefficient of variation for
homocysteine standards ranged from 5.5% for 0.5 μπιοί/
1 to 0.7% for 100 μιηοΐ/ΐ. The respective values for stan-
dards diluted in pool plasma were 4.9% and 1.5%. The
day to day (inter-assay) coefficient of variation was
8.4% for 0.5 μιηοΐ/ΐ and 4.1% for 100 μπιοΐ/l for stan-
dards in buffer and 6.3% and 5.2% for standards in
plasma, respectively.
The analytical recovery after adding known concentra-
tions of L-homocysteine (0.5 to 100 μιηο1/1) to human
plasma ranged from 94.9 to 117.0%. Data are shown in
table 1.
With the method described we subsequently studied to-
tal homocysteine plasma levels in 30 presumably heal-
thy male individuals (mean age: 38.3 ± 16.6 years) after
an overnight fast. Mean total homocysteine concentra-
tion in plasma in this group was 10.5 ± 4.3 μηιοΐ/ΐ and
thus in good agreement with previous published data
(8).
Discussion
Blood samples were collected following the method of
Fiskerstrand et al. (12) and Refsum et al. (13). They
could show that it is important to collect the blood in
prechilled EDTA-containing tubes followed by immedi-
ate centrifugation. Under these conditions the separation
of plasma and blood cells will prevent false positive re-
sults which otherwise may reflect the intracellular eryth-
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Fig. 2 Correlations between added and measured homocysteine
concentrations in buffer (a) and pooled plasma (b) for a concentra-
tion range from 0.5 to 100 μηιοΐ/ΐ. The plasma blank was subtracted
from the measured values. Means ± standard deviations each of
ten measurements were shown. Standard deviations not depicted
are within the symbols
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Tab. 1 Inter-assay recovery studies of homocysteine added to
plasma and homocysteine added to buffer (n = 10). Plasma values






















































Very recent studies have demonstrated that thiol-con-
taining amino acids are more stable in tubes containing
heparin as anticoagulant with sodium fluoride (16)
which may represent an alternative method for sample
stabilization.
Determination of total homocysteine requires the reduc-
tion of several species of homocysteine disulphides in
plasma. Several reducing reagents for liberating homo-
cysteine and other sulphur compounds from plasma pro-
teins have been described: dithiothreitol (17), tri-«-
butylphosphine (18), mercaptoethanol (19) and sodium
borohydride (12, 13). However, in our opinion, the so-
dium borohydride concentration used in these reports
was not appropriate. It was not sufficiently potent to
reduce all disulphide bonds and to prevent the re-oxida-
tion of homocysteine. At higher concentrations we no-
ticed strong foam formation despite the addition of octa-
nol leading to partial loss of the sample and poor recov-
ery (data not shown).
We also experienced difficulties with monobromobi-
mane as thiol-specific derivatization reagent (12,13) due
to a contamination resulting in an overlap of the relevant
peaks. In addition, this method is disadvantageous as it
requires a high cost programmable autosampler equip-
ment allowing eight derivatization-steps.
Therefore we decided to use a previously described
manual derivatization method by Araki & Sako (18) with
slight modifications. Smaller sample volumes were used
in order to economize reagents and to reduce sample
size. Plasma was deproteinized with perchloric acid in-
stead of trichloracetic acid. Tri-«-butylphosphine was
selected as reducing agent, allowing complete thiol lib-
eration within 30 minutes. 7-Fluoro-benzo-2-oxa-1.3-di-
azole-4-sulphonate as fluorescence agent requires 60
min for incubation at 60 °C for reacting with the free
thiols. This step is obviously inconvenient as compared
to the method of Refsum & Fiskerstrand (12, 13). It
increases, however, the specificity of the derivatization
step since this reagent does not react with alcohols, phe-
nols or amino groups. As another thiol-specific derivati-
sation reagent, 7-fluoro-benzo-2-oxa-1.3-diazole-4-sul-
phonamide (ABDF) was proposed by Cornwell (20). It
allows complete formation of the corresponding thiol
complex within 10 min. However, this sulphonamide
complex with homocysteine shows a markedly higher
retention time and thus would require to increase the
amount of acetonitrile up to 10% of the mobile phase in
order to achieve reasonably short running times.
Most methods published so far have used gradient sys-
tems that require rather long total running times beyond
10 min (12-14, 18). In addition, gradient systems are
more susceptible to irregularities as compared to isocratic
systems. An isocratic method has previously been de-
scribed by Ubbink et al. (21). As compared to the condi-
tions described here a rather high flow rate (2 rnl/min) is
necessary to elute the sulphonate homocysteine complex
from the column that also results in somewhat higher re-
tention times. Moreover, as outlined in this report the sep-
aration of homocysteine from cysteinylglycine is highly
sensitive to pH changes of the mobile phase. We have se-
lected a column with a high carbon load. Therefore, hy-
drophilic interactions of the analyte with free silica of the
column matrix are less important and rendered our separa-
tion much less pH-dependent.
The measurement of homocysteine was linear over the
physiologically and diagnostically relevant range of
concentrations. We observed higher concentrations only
in untreated homozygous homocystinuria and in this
case samples were diluted fivefold. However, this
limitation for high concentrations was not due to the
derivatization procedure itself but only to the fluores-
cence detector range. With another fluorescence-detector
the response was linear at least up to 1 mmol/1 homocys-
teine (data not shown).
As compared to other amino acids the normal amount
of homocysteine in human plasma is low. Therefore,
methods for homocysteine determination need to be fea-
sible, especially in the low concentration range. Our
method proved to be sufficiently precise and sensitive
to detect even small changes in homocysteine concentra-
tions which is considered a prerequisite for monitoring
therapeutic interventions. The results obtained for intra-
and inter-assay variability were compatible with those
of other Chromatographie assays. The analytical recov-
ery for homocysteine added to plasma was nearly com-
plete over the entire concentration range tested. The re-
covery for known concentrations of homocysteine added
to buffer, however, was somewhat more variable, espe-
cially in the low concentration range. This might be due
to interferences and/or absorption effects which are sup-
pressed by the plasma matrix.
Determination of homocysteine is receiving increasing
attention in medical diagnostics. Case-control (22),
cross-sectional (23) and prospective epidemiological
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studies (24) showed that moderately elevated homocys-
teine concentrations are associated with an increased
risk of atherosclerotic vascular disease. In a recent study
of 1100 patients, Seihub et al. (25) reported that 29.3%
of their cohort exhibited hyperhomocyst(e)inaemia, 67%
of those were found to have vitamin Be -deficiency. This
study has led to emphasize adequate dietary intake of
folate and vitamin supplements. Taken together, the
method devised, seems to be a procedure applicable to
the sensitive and precise measurement of total homocys-
teine in plasma in such instances and will potentially
benefit clinical researchers and nutritionists. The method
would be equally suitable for the determination of total
cysteine if needed for special purposes.
Diagnosis of this independent risk factor for athero-
sclerosis has the potential for reducing the incidence of
cardiovascular diseases by intervention with an inexpen-
sive vitamin therapy not only in elderly patients but also
in the general population.
Fully automated fluorescence polarisation immuno-
assays for homocysteine have already been published
but not introduced (26). Therefore an accurate, rapid and
cheap HPLC-method for quantifying total homocysteine
will help to identify patients who might benefit from the
intervention.
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